
- Volume 0 0
National Standards for Pseudoephedrine OTCs?
Responding to a series of recentstate actions restricting the retail saleof OTC pseudoephedrine products, thechain drugstore industry is calling fornew national standards that wouldlimit distribution of these drugs tolicensed pharmacies.
The plan, advanced by the NationalAssociation of Chain Drug Stores(NACDS) as a move to combat illegalmethamphetamine production, wouldpreempt all state laws that currentlyrestrict sales of OTC pseudoephedrinedrugs, such as Sudafed and Theraflu,and would keep these products availableto patients without a prescription.
Single-entity pseudoephedrine productscould be sold only by a licensedpharmacist or pharmacy aide frombehind the prescription counter, however.Combination products containingpseudoephedrine would be subjectto similar restrictions effective January1, 2007.
The NACDS proposal also wouldlimit purchases of these OTCs to 9 gwithin a 30-day period. Pharmacieswould be required to maintain a writtenor electronic log of all purchases toassist law enforcement officials.
The chain drug group's officials saidthat these principles for a nationwidestandard to regulate sales of pseudoephedrinedrugs would "strike a balancebetween keeping valuable productsavailable to our consumers and combatingdangerous, illegal practices."
Mr. Rankin is a freelance medical writer.
Articles in this issue
over 20 years ago
Antibiotics, Probiotics, and Microfloraover 20 years ago
Calcium: An Essential Mineralover 20 years ago
CAN YOU READTHESE Rxs?over 20 years ago
ECKEL RECEIVES ALUMNI AWARDover 20 years ago
Cancer: Update on Biologicsover 20 years ago
Managing Chronic Pain: An Analysis of the Use of Opioidsover 20 years ago
PHARMACIST'S RIGHT TO CHOOSE?over 20 years ago
Teenage Drug Diversion—Part 2over 20 years ago
Is Altering Refills a Criminal Act?over 20 years ago
Do All SSRIs Interact the Same Way?Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.